Gene test guides treatment for rare salivary gland tumors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Phase 1, Molecular Profiling): * Have available archival tumor tissue or fresh tumor specimen from diagnostic histological tissue for molecular profiling. * Histological or cytological proof of malignant salivary gland tumor * ECOG performance score 0-2 * Documented evidence of recurrent or metastatic disease Inclusion Criteria (Phase 2, Treatment): * Interpretable result of molecular profiling in the molecular profiling phase of this study * Advanced recurrent or metastatic salivary gland cancer for which no curative therapy exists * Evidence of clinical or radiological disease progression at the time of study treatment * At least one measurable target lesion as defined by RECIST 1.1 * Must have adequate hematological, liver, renal and cardiac function * No concomitant use of drugs which may prolong QTc interval * No history of serious cardiac illness * No serious medical conditions that might be aggravated by treatment or limit compliance. * Central nervous system metastases are permitted provided these are clinically stable * Able to take oral medication and have no evidence of bowel obstruction, infectious/inflammatory bowel disease * No other active malignancy at any other site * 18 years of age or older * Measureable disease as defined by RECIST v1.1 * Not receiving any other concurrent investigational agent * If the matched treatment is in the context of another phase I trial, the eligibility criteria of the enrolled trial will be used instead of the criteria from this trial Exclusion Criteria (Phase 1, Molecular Profiling): * Refuses to have tumor tissue undergo molecular profiling * Not enough tumor tissue for molecular profiling * Life expectancy less than 3 months Exclusion Criteria (Phase 2, Treatment): * Had stopped the previous treatment but showed no clinical or radiological evidence of disease progression * Have received the same drug treatment of assignment to the specific arm before the enrolment in to treatment phase (phase 2)